Search Results - "Capelletto, E."

Post-survey data about “I do not smoke it”, smoking prevention campaign addressed to schools by Rapetti, S.G., Biglia, C., Capelletto, E., Galetta, D., Baffunno, D., Binato, S., Marchese, F., Ferraresi, F., Novello, S.

Get full text

DNA amount comparison between cytologic and histologic samples for epithelial growth factor receptor (EGFR) testing in non-small-cell lung cancer (NSCLC) patients: a single institution experience by Gobbini, E., Reale, M.L., De Luca, E., Righi, L., Gianetta, M., Capelletto, E., Buffoni, L., Giaj Levra, M., Novello, S.

Get full text

The standard of care for stage III NSCLC in the era of immunotherapy: An Italian national survey on the current pattern of care among Italian thoracic oncologists by Bruni, A., Grossi, F., Katia, F., Capelletto, E., Buffoni, L., Badellino, S., Poletti, V., Chiari, R., Giaj Levra, N., Banna, G.L., Vagge, S., Borghetti, P., Baldini, E., Bria, E., Tiseo, M., Paci, M., Ciammella, P., Taraborrelli, M., Ricardi, U., Scotti, V.

Get full text

Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial by Morelli, A.M., Migliorino, M.R., Morabito, A., Chiari, R., Grossi, F., Bordi, P., Di Costanzo, F., Delmonte, A., Romano, G., Misino, A., Scotti, V., Gregorc, V., Pisconti, S., Ceresoli, G.L., Del Conte, A., Colantonio, I., Ciuffreda, L., Capelletto, E., Stura, I., Novello, S.

Get full text

Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program by Metro, G., Passaro, A., Lo Russo, G., Bonanno, L., Giusti, R., Gregorc, V., Capelletto, E., Martelli, O., Cecere, F.L., Giannarelli, D., Luciani, A., Bearz, A., Tuzi, A., Scotti, V., Tonini, G., Galetta, D., Carta, A., Soto Parra, H., Morabito, A., Chiari, R.

Get full text

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis by Duruisseaux, Michäel, Martínez-Cardús, Anna, Calleja-Cervantes, Maria E, Moran, Sebastian, Castro de Moura, Manuel, Davalos, Veronica, Piñeyro, David, Sanchez-Cespedes, Montse, Girard, Nicolas, Brevet, Marie, Giroux-Leprieur, Etienne, Dumenil, Coraline, Pradotto, Monica, Bironzo, Paolo, Capelletto, Enrica, Novello, Silvia, Cortot, Alexis, Copin, Marie-Christine, Karachaliou, Niki, Gonzalez-Cao, Maria, Peralta, Sergio, Montuenga, Luis M, Gil-Bazo, Ignacio, Baraibar, Iosune, Lozano, Maria D, Varela, Mar, Ruffinelli, Jose C, Palmero, Ramon, Nadal, Ernest, Moran, Teresa, Perez, Lidia, Ramos, Immaculada, Xiao, Qingyang, Fernandez, Agustin F, Fraga, Mario F, Gut, Marta, Gut, Ivo, Teixidó, Cristina, Vilariño, Noelia, Prat, Aleix, Reguart, Noemi, Benito, Amparo, Garrido, Pilar, Barragan, Isabel, Emile, Jean-François, Rosell, Rafael, Brambilla, Elisabeth, Esteller, Manel

“…Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung cancer (NSCLC) has improved the survival of patients. However, a substantial…”
Get full text

1617P Impact of nutritional counselling (NC) on CT-based body composition in patients with oncogene addicted advanced non-small cell lung cancer (aNSCLC) by Morelli, A.M., Bungaro, M., Capizzi, I., Parlagreco, E., Solitro, F., Eletti, L., Martinetto, S., Veltri, A., Tinivella, M., Pedrazzoli, P., Caccialanza, R., Bertaglia, V., Capelletto, E., Reale, M.L., Novello, S., Tampellini, M.

Get full text

1355P Clinical trial enrollment among lung cancer patients: A real-world multicenter analysis by Reale, M.L., Capelletto, E., Buttigliero, C., Bordi, P., Ricciardi, S., Belluomini, L., Garbo, E., Leonetti, A., Lombardi, A., Dodi, A., Napoli, V., Casali, M., Soregaroli, D., Insolda, J., Bironzo, P., Tiseo, M., Migliorino, M.R., Pilotto, S., Passiglia, F., Novello, S.

Get full text

1676P Nutritional assessment in the era of targeted therapies in advanced non-small cell lung cancer (aNSCLC) oncogene-addicted patients by Morelli, A.M., Capizzi, I., Pisano, C., De Filippis, M., Carnio, S., Alemanni, A., Tinivella, M., Pedrazzoli, P., Caccialanza, R., Bertaglia, V., Capelletto, E., Bironzo, P., Reale, M.L., Tampellini, M., Novello, S.

Get full text

1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients by Mariniello, A., Tabbò, F., Indellicati, D., Geuna, M., Tesauro, M., Rezmives, N.A., Di Maio, M., Bironzo, P., Reale, M.L., Passiglia, F., Listi, A., Capelletto, E., Carnio, S., Bertaglia, V., Mecca, C., Consito, L.T., De Filippis, M., Bungaro, M., Paratore, C., Novello, S.

Get full text

A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM) by Tagliamento, M., Bironzo, P., De Luca, E., Pignataro, D., Rapetti, S.G., Audisio, M., Bertaglia, V., Paratore, C., Bungaro, M., Olmetto, E., Artusio, E., Reale, M.L., Zichi, C., Capelletto, E., Carnio, S., Buffoni, L., Passiglia, F., Novello, S., Di Maio, M.

Get full text

1588TiP - The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer by Passiglia, F., Capelletto, E., Grossi, F., Bidoli, P., Galetta, D., Follador, A., Valmadre, G.P., Defferrari, C., Caffo, O., Bearz, A., Colantonio, I., Gregorc, V., Scotti, V., Cognetti, F., Cordero, L., Arizio, F., Novello, S., Torri, V., Scagliotti, G.

“…Non-small cell lung cancer (NSCLC) is one of the commonest disease worldwide and the leading cause of cancer-related death. Incidence increases with age and…”
Get full text

1588TiPThe elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer by Passiglia, F, Capelletto, E, Grossi, F, Bidoli, P, Galetta, D, Follador, A, Valmadre, G P, Defferrari, C, Caffo, O, Bearz, A, Colantonio, I, Gregorc, V, Scotti, V, Cognetti, F, Cordero, L, Arizio, F, Novello, S, Torri, V, Scagliotti, G

“…Abstract Background Non-small cell lung cancer (NSCLC) is one of the commonest disease worldwide and the leading cause of cancer-related death. Incidence…”
Get full text

Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial by Capelletto, E., Morabito, A., Grossi, F., Costanzo, F Di, Osman, G., Chiari, R., Bordi, P., Scotti, V., Romano, G., Delmonte, A., Galetta, D., Ciuffreda, L., Manzo, A., Genova, C., Mazzoni, F., Morelli, A.M., Critelli, R., Stura, I., Migliaretti, G., Novello, S.

Get full text

1568P - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial by Capelletto, E., Morabito, A., Grossi, F., Costanzo, F Di, Osman, G., Chiari, R., Bordi, P., Scotti, V., Romano, G., Delmonte, A., Galetta, D., Ciuffreda, L., Manzo, A., Genova, C., Mazzoni, F., Morelli, A.M., Critelli, R., Stura, I., Migliaretti, G., Novello, S.

“…The SENECA trial showed similar progression free survival (PFS) and overall survival (OS) in non-squamous non-small cell lung cancer (nsNSCLC) patients (pts)…”
Get full text

The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer by Passiglia, F., Capelletto, E., Grossi, F., Bidoli, P., Galetta, D., Follador, A., Valmadre, G.P., Defferrari, C., Caffo, O., Bearz, A., Colantonio, I., Gregorc, V., Scotti, V., Cognetti, F., Cordero, L., Arizio, F., Novello, S., Torri, V., Scagliotti, G.

Get full text

1568PPost progression survival for patients treated with docetaxel/nintedanib in the SENECA trial by Capelletto, E, Morabito, A, Grossi, F, Costanzo, F Di, Osman, G, Chiari, R, Bordi, P, Scotti, V, Romano, G, Delmonte, A, Galetta, D, Ciuffreda, L, Manzo, A, Genova, C, Mazzoni, F, Morelli, A M, Critelli, R, Stura, I, Migliaretti, G, Novello, S

“…Abstract Background The SENECA trial showed similar progression free survival (PFS) and overall survival (OS) in non-squamous non-small cell lung cancer…”
Get full text

Efficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: Results of the Italian compassionate use program by Metro, G., Passaro, A., Lo Russo, G., Gregorc, V., Giusti, R., Capelletto, E., Martelli, O., Cecere, F.L., Bonanno, L., Chiari, R.

Get full text

Immunotherapy (ImT), what Lung Cancer and Melanoma patients (pts) … and physicians, know by Capelletto, E., Novello, S., Ascierto, P.A., Michiara, M., Hauber, F., Furia, R., Gianetta, M., Vallone, S., Pinto, C.

Get full text

1376PThe standard of care for stage III NSCLC in the era of immunotherapy: An Italian national survey on the current pattern of care among Italian thoracic oncologists by Bruni, A, Grossi, F, Katia, F, Capelletto, E, Buffoni, L, Badellino, S, Poletti, V, Chiari, R, Giaj Levra, N, Banna, G L, Vagge, S, Borghetti, P, Baldini, E, Bria, E, Tiseo, M, Paci, M, Ciammella, P, Taraborrelli, M, Ricardi, U, Scotti, V

Get full text